Výsledky vyhledávání - "Takayuki Kii"

Akademický článek

Long‐term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5‐fluorouracil vs docetaxel, cisplatin, and 5‐fluorouracil followed by surgery for esophageal cancer (OGSG1003)

Autor: Keijiro Sugimura, Makoto Yamasaki, Takushi Yasuda, Masahiko Yano, Motohiro Hirao, Kazumasa Fujitani, Yutaka Kimura, Hiroshi Miyata, Masaaki Motoori, Atsushi Takeno, Osamu Shiraishi, Tomoki Makino, Takayuki Kii, Koji Tanaka, Taro Satoh, Masaki Mori, Yuichiro Doki

Publikováno v: Annals of Gastroenterological Surgery, Vol 5, Iss 1, Pp 75-82 (2021)

Abstract Aim The aim is to report the long‐term outcomes of preoperative cisplatin and fluorouracil plus docetaxel (DCF) vs Adriamycin (ACF) for resectable esophageal squamous cell carcinoma (ESCC). Previously, this trial showed that DCF is associa

Externí odkaz: https://doaj.org/article/66bed07f867546eeb9fcf40f3ad6b2bd

Zobrazit plný text záznamu

Sequential Treatment Strategy Using Fluoropyrimidine plus Bevacizumab Followed by Oxaliplatin for Metastatic Colorectal Cancer: A Phase II Study (OGSG 1107)

Autor: Toshifumi Yamaguchi, Motoki Yoshida, Hisato Kawakami, Takayuki Kii, Hiroko Hasegawa, Takahiro Miyamoto, Tetsuji Terazawa, Fukutaro Shimamoto, Masayoshi Yasui, Daisuke Sakai, Toshio Shimokawa, Yukinori Kurokawa, Masahiro Goto, Taroh Satoh

Publikováno v: Gastrointest Tumors

Introduction: Previous prospective studies suggest that the sequential use of cytotoxic agents, such as oxaliplatin, in patients with metastatic colorectal cancer (mCRC) has the potential to improve prognosis and maintain quality of life than combina

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6fbe943133470a9e71415b4ca6345d7
https://doi.org/10.1159/000522610

Zobrazit plný text záznamu

330. RANDOMIZED PHASE II STUDY OF DOCETAXEL VERSUS PACLITAXEL IN PATIENTS WITH ESOPHAGEAL SCC REFRACTORY TO FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY: OGSG1201

Autor: Jin Matsuyama, Sachiko Yamamoto, Takayuki Kii, Hiroki Hara, Ryohei Kawabata, Junji Kawada, Atsushi Takeno, Shugo Ueda, Hisato Kawakami, Yoshihiro Okita, Shunji Endo, Yutaka Kimura, Kazuhiro Yanagihara, Tatsuya Okuno, Yukinori Kurokawa, Toshio Shimokawa, Taroh Satoh

Publikováno v: Diseases of the Esophagus. 35

There is no standard chemotherapy for esophageal squamous cell carcinoma (ESCC) refractory to first-line fluoropyrimidine- and platinum-based chemotherapy. We therefore performed a randomized, selection-design phase II trial to compare docetaxel (DTX

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b0261fc7b959be33bd377df2b8ab2a6f
https://doi.org/10.1093/dote/doac051.330

Zobrazit plný text záznamu

A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404)

Autor: Motoo Nomura, Takayuki Kii, Junji Kawada, Masashi Hirota, Takashi Ohta, Jin Matsuyama, Daisuke Sakai, Toshio Shimokawa, Yukinori Kurokawa, Hisato Kawakami, Toshimasa Tsujinaka, Taroh Satoh

Publikováno v: Esophagus : official journal of the Japan Esophageal Society. 19(4)

Fluorouracil (FU), platinum (PT), and taxane (TAX) therapy was the standard chemotherapy for esophageal squamous cell carcinoma (ESCC) before the era of anti-programmed death-1 antibodies. The aim of this phase II trial was to evaluate the efficacy a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1be398a7d43c5bc4cd4d1aae900104b
https://pubmed.ncbi.nlm.nih.gov/35723843

Zobrazit plný text záznamu

A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer

Publikováno v: Annals of Surgical Oncology. 27:460-467

A multicenter phase 2 trial analysed chemoselection with docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy (ICT) and subsequent conversion surgery (CS) for locally advanced unresectable esophageal cancer. This study presents up

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8add9453b9c5c92151a7a7e71af27927
https://doi.org/10.1245/s10434-019-07654-8

Zobrazit plný text záznamu

Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201

Autor: Shugo Ueda, Yoshihiro Okita, Ryohei Kawabata, Sachiko Yamamoto, Tatsuya Okuno, Jin Matsuyama, Atsushi Takeno, Hisato Kawakami, Yukinori Kurokawa, Takayuki Kii, Taroh Satoh, Kazuhiro Yanagihara, Hiroki Hara, Junji Kawada, Shunji Endo, Yutaka Kimura, Toshio Shimokawa

Publikováno v: European journal of cancer (Oxford, England : 1990). 154

Background There is no standard chemotherapy for esophageal squamous cell carcinoma (ESCC) refractory to first-line fluoropyrimidine- and platinum-based chemotherapy. We therefore performed a randomized, selection-design phase II trial to compare doc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed350ad82fa26ac18e9f8a27b1417a56
https://pubmed.ncbi.nlm.nih.gov/34311300

Zobrazit plný text záznamu

Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003)

Autor: Masaki Mori, T. Satoh, Atsushi Takeno, Hiroshi Miyata, Keijiro Sugimura, Takayuki Kii, Masaaki Motoori, Makoto Yamasaki, Yutaka Kimura, Kazumasa Fujitani, Koji Tanaka, Motohiro Hirao, Takushi Yasuda, Osamu Shiraishi, Yuichiro Doki, Tomoki Makino, Masahiko Yano

Publikováno v: Annals of Gastroenterological Surgery
Annals of Gastroenterological Surgery, Vol 5, Iss 1, Pp 75-82 (2021)

Aim The aim is to report the long‐term outcomes of preoperative cisplatin and fluorouracil plus docetaxel (DCF) vs Adriamycin (ACF) for resectable esophageal squamous cell carcinoma (ESCC). Previously, this trial showed that DCF is associated with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d7f6b832f56a156a0106e8d9d23c2ed
https://hdl.handle.net/11094/78301

Zobrazit plný text záznamu

Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer

Autor: Keitaro Tanaka, Masahiro Goto, Takayuki Kii, Futukaro Shimamoto, Masashi Yamamoto, Hiroyuki Kodama, Yasunobu Ishizuka, Hiroki Yukami, Tetsuji Terazawa, Masahiko Aoki, J. Okuda, Wataru Osumi, Toshifumi Yamaguchi, Kazuhisa Uchiyama, Hiroki Hamamoto, Kazuhide Higuchi, Takahiro Miyamoto

Publikováno v: In Vivo

Background/aim Neoadjuvant chemotherapy without radiation (NAC) shows favorable outcomes for locally advanced rectal cancer (LARC), however, the optimal regimen has not been determined yet. This study aimed to compare the efficacy and safety of oxali

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9105644cf7d5d82367c32be4186808e7
https://pubmed.ncbi.nlm.nih.gov/33622892

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání